Sequencing data for this project have been deposited in the National Center for Biotechnology Information, NIH, Sequencing Read Archive (www.ncbi.nlm.nih.gov/sra), PRJNA294804. We thank M. Chung, C. Anderson, E. Wagner, J. Lyons, and members of the Levine and Rokhsar labs for helpful discussions. This work was supported by grants from the NIH (GM46638 and NS076542). There are no conflicts of interest to declare. Author contributions are as follows: E.K.F., D.S.R., and M.S.L. devised experiments; E.K.F. and K.M.O. performed experiments; W.Z. designed and executed bioinformatics analysis; A.J.B. conducted bioinformatics analyses; and E.K.F., D.S.R., and M.S.L. wrote the paper. All authors discussed the results and commented on the manuscript. M.S.L., D.S.R., and E.K.F. have filed a patent application (no. 62/169,458) that relates to the production of enhancer variants using the SEL-Seq method. Rosa Barreira da Silva, 1, 2 Caetano Reis e Sousa, 5 Douglas R. Green, 6 Andrew Oberst, 4 Matthew L. Albert 1,2 * Dying cells initiate adaptive immunity by providing both antigens and inflammatory stimuli for dendritic cells, which in turn activate CD8 + T cells through a process called antigen cross-priming. To define how different forms of programmed cell death influence immunity, we established models of necroptosis and apoptosis, in which dying cells are generated by receptor-interacting protein kinase-3 and caspase-8 dimerization, respectively. We found that the release of inflammatory mediators, such as damage-associated molecular patterns, by dying cells was not sufficient for CD8 + T cell cross-priming. Instead, robust cross-priming required receptor-interacting protein kinase-1 (RIPK1) signaling and nuclear factor kB (NF-kB)-induced transcription within dying cells. Decoupling NF-kB signaling from necroptosis or inflammatory apoptosis reduced priming efficiency and tumor immunity. Our results reveal that coordinated inflammatory and cell death signaling pathways within dying cells orchestrate adaptive immunity. P hagocytosis of dying cells by dendritic cells (DCs) results in cross-presentation of cellassociated antigen and the priming of CD8 + T cells (1) . This pathway mediates the processing and presentation of tumor antigens (2), as well as viral and self proteins in instances where expression is restricted to nonhematopoietic cells (3, 4) . However, the manner by which different forms of programmed cell death (PCD) influence the ability of DCs to cross-present and initiate CD8 + T cell responses is still poorly understood.
Until recently, apoptosis was thought to be immunologically quiescent, in contrast to necrosis, which is characterized by rapid membrane permeabilization and the release of inflammatory mediators called damage-associated molecular patterns (DAMPs). Paradoxically, the inflammatory nature of necrotic cells (defined by their ability to activate innate immune cells) (5-8) does not correlate with their ability to serve as a source of antigen for the initiation of CD8 + T cell immunity (defined as immunogenicity) (1, (9) (10) (11) (12) . Moreover, immunogenic cell death has often been associated with apoptotic pathways (1, 10, (13) (14) (15) . Several recent studies highlighted the interconnections between cell death and inflammatory signal transduction. For example, proteins such as receptor-interacting protein kinase-3 (RIPK3) and caspase-8, which respectively initiate necroptosis and apoptosis, are incorporated into dynamic innate immune signaling modules (e.g., ripoptosome) (16) (17) (18) (19) . These cytosolic scaffolds establish the cross-talk between innate immune and cell death programs, and, in some instances, both pathways may be simultaneously engaged ( fig. S1A ). This integration of pathways, combined with the recent discovery of necroptosis (a regulated form of necrosis), prompted us to reevaluate how different PCD pathways affect cross-priming of CD8 + T cells. To selectively induce apoptosis or necroptosis, we constructed "pure" cell death systems, in which the death effector proteins caspase-8 or RIPK3 were fused to a modified FK506 binding protein (FKBP) domain (Fv-DN-caspase-8 and RIPK3-2xFv, respectively) (20) (21) (22) (fig. S1B ). RIPK3 oligomerization results in the recruitment of RIPK1 via interactions with the RIPK3-RIP homotypic interaction motif (RHIM RIPK3 ) domain, leading to the formation of a cytosolic ripoptosome-like complex (21, 23) . Therefore, we also generated a Cterminally truncated construct (RIPK3DC-2xFv) (fig. S1B), which lacks the RHIM RIPK3 domain and does not recruit RIPK1 (21) . NIH 3T3 cells were stably transduced with these activatable constructs (referred to herein as acC8, acR3, and acR3DC). Dimerization of caspase-8 resulted in the induction of apoptosis, whereas oligomerization of full-length RIPK3 and RHIM-less RIPK3 induced rapid cell swelling and membrane rupture (<3 hours) in the absence of caspase activation (Fig. 1, A and B; fig. S2 , A to C; and movies S1 to S3). The ability to induce necroptosis in the absence of the RHIM RIPK3 domain enabled us to decouple the formation of RIPK1-dependent ripoptosome complex from cell death (21) , hence eliminating the activation of other pathways emanating from the ripoptosome.
Cell death-associated molecules such as calreticulin (CRT), adenosine triphosphate (ATP), and high-mobility group box-1 (HMGB1) have been shown to trigger inflammation and to regulate immunogenic cell death (8, 15, (24) (25) (26) . We therefore quantified CRT surface exposure and the release of both ATP and HMGB1 by apoptotic or necroptotic cells. Low levels of CRT exposure were observed during the three forms of cell death, and only the acR3-and acR3DC-expressing NIH 3T3 cells rapidly released high concentrations of ATP and HMGB1 upon treatment (Fig. 1, C to E) . In all cases, no detectable levels of interleukin1a (IL-1a), IL-1b, or uric acid were released. We next evaluated phagocytosis by DCs (i.e., acquisition of antigen) and subsequent DC maturation, which are two steps required for achieving CD8 + T cell cross-priming (27, 28) . We found that bone marrow-derived dendritic cells (BMDCs) and a CD8a + DC-derived cell line (MuTuDC) acquired similar amounts of dimerizer-treated acC8-, acR3-, SCIENCE sciencemag.org P values for (F) were determined by the one-way ANOVA test; P values for (G) were determined by the Kruskal-Wallis test (multigroup comparision), followed by Dunn's post-test, comparing each group to the PBS group. *P < 0.05; ****P < 0.0001; NS, not significant. acC8, caspase-8 apoptosis; acR3, RIPK3 necroptosis; acR3DC, RHIM-less RIPK3 necroptosis.
sciencemag.org SCIENCE For (A) and (B), P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test; for (D) and (F), P values were determined by the Mann-Whitney test; and in (G), mice survival percentages were compared using the log-rank test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. acC8-, acR3-, and acR3DC-expressing NIH 3T3 cells were treated with dimerizer. At the indicated times, protein extracts were analyzed by Western blot (n = 2 independent experiments) (A); RNA was extracted for transcriptional profiling (n = 3 independent experiments) (B), or culture supernatants were collected for luminex analysis [(C) and (D)]. (E to H) We quantified the release of IL-6 release upon addition of dimerizer, after treating the cells as follows: In (E), 2 mg/ml of ActD or 2.5 mg/ml of CHX were added at the indicated times, after the addition of dimerizer (0 hours), and IL-6 was measured at 6 hours. In (F), cells were preteated with 10 mM of Wedelolactone (NFkBi), and IL-6 was measured at the indicated times. In (G), acR3 cells that were stably expressing the control vector (acR3-vector) or the mutant SR IkB (acR3-SR) were used. In (H), control NIH 3T3 cells (Tet-acR3), and cells lacking RIPK1 and expressing RIPK3 2xFv under a tetracycline promoter (Tet-acR3-ripk1 −/− ), were treated overnight with 500 ng/ml of doxycycline before the addition of dimerizer. In (C) to (H), the data are presented as means (± SEM) of triplicates from one representative experiment (n ≥ 2 independent experiments). The heat map indicates the relative expression of the indicated transcript (red indicates high levels and green indicates low levels of expression). fig. S4,  A and B) . Moreover, both acR3 and acR3DC induced the up-regulation of DC activation markers, whereas acC8-expressing NIH 3T3 cells did not (Fig. 1F and fig. S4C ). Similarly, intraperitoneal injection of dimerizer-treated acR3-or acR3DC-expressing cells induced higher recruitment of immune cells, as compared with injection of acC8-expressing cells (Fig. 1G) . Together, these data suggest that necroptotic cells released DAMPs, induced maturation of DCs in vitro, and induced inflammation in vivo.
To assess the respective immunogenicity of apoptotic and necroptotic cells, we immunized C57BL/6 mice by intradermally injecting 10 6 dimerizer-treated NIH 3T3 cells that stably expressed a nonsecretable form of ovalbumin (OVA) ( fig. S5A) (29) . Cells were exposed to dimerizer immediately before injection, thereby enabling them to undergo cell death in situ. We observed significantly higher CD8 + T cell cross-priming when mice were immunized with cells undergoing RIPK3-mediated necroptosis than with cells undergoing caspase-8-mediated apoptosis ( Fig. 2A  and fig. S5B ; P < 0.0001). Immunization with acR3DC-OVA NIH 3T3 cells did not result in robust CD8 + T cell cross-priming ( Fig. 2A and fig.  S5B ; P < 0.01 in a comparison with acR3-OVA NIH 3T3 cells), indicating that RHIM-dependent interactions are required for the immunogenicity of necroptotic cells.
We next compared the cross-priming efficiency of cells undergoing necroptosis with that of cells undergoing unregulated necrosis, such as "mechanical" necrosis (also called primary necrosis, and achieved by repeated freezing and thawing) or "secondary" necrosis (achieved by incubating apoptotic cells for 24 hours before immunization). We found that mechanical and secondary necrotic cells induced only weak CD8 + T cell responses ( Fig. 2B ; P < 0.01). Although the latter results could be partially explained by the loss of antigen after necrotic membrane permeabilization ( fig. S6) , the findings suggest that in vivo necroptosis is a more efficient inducer of cross-priming, as compared with apoptotic or necrotic cells.
The efficiency and outcome of antigen crosspresentation have been shown to depend on a subset of CD8a + -CD103
+ DCs, whose differentiation is driven by the transcription factor for the Batf3 gene (30 ) were poly I:C-transfected and injected into Balb/cByJ mice. Seven days later, spleens and lymph nodes were harvested, and IFN-g production was quantified (G). In (H), mice were challenged with 5 × 10 5 WT CT26 cells injected in the opposite flank, and tumor growth was monitored every 3 days. Results are from one representative experiment with six mice per group (n = 3 independent experiments). P values were determined by the Mann-Whitney test [(A) to (G)] or the two-way ANOVA test (multiple group comparison, comparing each group to the NI group) (H). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
a CD8 + T cell response ( fig. S7, A and B) , confirming that cross-presentation of antigen associated with necroptotic cells is mediated by this DC lineage. We next characterized the CD8 + T cells induced by acR3-OVA immunization. CD8 + T cells primed by immunization with necroptotic cells produced multiple effector cytokines (Fig. 2,  C and D) , exhibited in vivo cytolytic activity (Fig. 2,  E and F) , and protected mice from tumor challenge (Fig. 2G) . Together, these data indicate that necroptotic cells are able to provide both antigen and immune stimulation, in turn supporting DCmediated cross-priming of CD8 + T cells. The requirement of RHIM RIPK3 for the immunogenicity of necroptotic cells suggests that classical DAMPs (e.g., HMGB1) are insufficient to achieve robust cross-priming and supports a critical role for RIPK1, independent of cell death.
To understand the requirement of RHIM for immunogenic necroptosis, we studied the signaling pathways that were engaged during the different forms of cell death and assessed mitogen-activated protein kinase (MAPK) and NF-kB activation after dimerizer treatment. Oligomerization of RIPK3 in acR3-expressing NIH 3T3 cells resulted in the rapid phosphorylation of p38 and extracellular signal-regulated kinase-1 and -2 and the degradation of IkB (Fig. 3A) . Activation of these inflammatory pathways was not observed after dimerization of caspase-8 and was attenuated in acR3DC-expressing NIH 3T3 cells, with the greatest difference corresponding to the NF-kB pathway (Fig. 3A) . To determine the impact on the transcriptional profile, we quantified the mRNA expression of 179 immune-related genes at different stages of cell death (Fig. 3B) . Despite the rapid cell death kinetics, full-length RIPK3 activation triggered a significant up-regulation of 72 inflammatory genes, many of which are regulated by NF-kB and MAPK activation ( fig. S8A and table S1; rank regression on time with adjustment for false discovery rate, q < 0.05). In contrast, we observed only modest changes in dimerizer-treated acC8-expressing cells (three genes differentially expressed) and acR3DC-expressing cells (17 genes differentially expressed) ( fig. S8A and table S1). We next measured inflammatory cytokines in the supernatant from dimerizertreated cell cultures and found that acR3 cells released high amounts of IL-6 (Fig. 3C) and CXCL1 (Fig. 3D) , validating our transcriptional analysis. IL-6 production was inhibited in a time-dependent manner by treating the cells with actinomycin-D (ActD) or cycloheximide (CHX) (Fig. 3E) . These data suggest that necroptotic cells actively transcribe and translate inflammatory cytokines during cell death ( fig. S8B) . Moreover, chemical inhibition of IKK kinase activity diminished the release of IL-6 (Fig. 3F) , and stable expression of an IkB dominant negative protein [NF-kB (S32A, S36A) super repressor, SR] also inhibited cytokine secretion (Fig. 3G) .
To formally test the contribution of RIPK1, we deleted RIPK1 from NIH 3T3 cells and stably expressed the RIPK3-2xFv construct under a tetracycline-inducible promoter (Tet-acR3) (fig.  S9, A and B) . The addition of dimerizer triggered necroptosis in both cell lines (fig. S9C) ; however, NF-kB activation ( fig. S9D ) and IL-6 production ( Fig. 3H) were reduced in the cells lacking RIPK1. These results revealed an NF-kB transcriptional and translational activity that is engaged during RIPK3 necroptosis.
We next tested the hypothesis that RIPK1 signaling and NF-kB-dependent gene expression within the dying cell are critical for cross-priming. We immunized mice using necroptotic cells that lacked RIPK1 (Tet-acR3-Ripk1 −/− ) (Fig. 4A) , cells that lacked NF-kB signaling [pretreated with NFkB inhibitor (NFkBi) (Fig. 4B) or overexpressing the NF-kB SR (Fig. 4C)] , or cells in which transcription was inhibited (pretreated with ActD) (Fig. 4D) . Cross-priming was significantly reduced in all instances, thus establishing that active RIPK1-NF-kB signaling is essential for the immunogenicity of necroptotic cells.
To extend our findings to a second model that leads to simultaneous RIPK1-dependent NF-kB activation and cell death, we used the transfection of polyinosinic-polycytidylic acid (poly I:C) ( fig. S10A) , which engages the cytosolic RNA sensors RIG-I and MDA5, in turn recruiting the adaptor proteins IPS-1, RIPK1, TRADD, and FADD (31) . We confirmed that in this model, RIPK1 was essential for NF-kB activation ( fig. S10 , B and C) and cytokine secretion ( fig. S10D) (31) . Moreover, poly I:C transfection results in intrinsic apoptosis, rather than necroptosis (32) . We found that in both wild-type (WT) and Ripk1 −/− cells, poly I:C is capable of inducing similar levels of caspase-3 activation and cell death (fig. S10, E and F). Thus, we were able to decouple NF-kB activation from apoptosis induction downstream of doublestranded RNA sensors. We next tested the hypothesis that immunogenic apopotosis induced by poly I:C (33) was regulated by the RIPK1-NF-kB axis. We immunized mice with poly I:C-transfected OVA-expressing mouse embryonic fibroblasts (MEFs) (Fig. 4, E 
and F). Compared with immunization with WT cells, immunization with Ripk1
−/− (Fig. 4E) or NF-kB SR-expressing cells (Fig. 4F ) resulted in a significant reduction in CD8 + T cell priming. These data reinforce the crucial role of RIPK1-mediated NF-kB activation within dying cells during the initiation of CD8 + T cell immune responses, despite the presence of a strong inflammatory pathogen-associated molecular pattern such as poly I:C.
Finally, we tested the relevance of our findings in the context of tumor immunity. Deletion of RIPK1 from poly I:C-transfected CT26 colon carcinoma cells ( fig. S10G ) rendered them poorly immunogenic in comparison with WT cells, as measured by interferon-g (IFN-g) production ( Fig. 4G ) and protection from tumor challenge (Fig. 4H) . Overall, our results reveal RIPK1-induced NF-kB activation as the critical determinant of CD8 + T cell immunity to cell-associated antigens. The danger model predicts that cell death resulting from tissue damage and stress induces the passive release of preformed danger molecules that mediate subsequent immune responses (34) . Breaking from this model, the present study reveals an unexpected role for RIPK1-and NF-kBdriven gene expression during cell death as a key determinant for cross-priming of CD8 + T cells. Thus, although the release of DAMPs can trigger inflammatory responses, we show that RIPK1-mediated induction of NF-kB and its downstream target genes is necessary for initiating CD8 + T cell adaptive immunity. To date, PCD pathways have been defined by morphological and biochemical methods; our results highlight the need for a transcriptional definition of cell death, as a means of understanding the relationship between dying cells and immunity. Whether these findings apply to other aspects of adaptive immunity (e.g., B cell or CD4 T cell priming) remains to be determined (7, 35) .
NF-kB is a critical regulator of innate immune responses, and its pathway is a prime target of interference by pathogens; our results suggest an additional benefit for microbes that interfere with both NF-kB signaling (36) and cell death pathways (37, 38) . For example, viral inhibitors of RHIM-dependent interactions (e.g., mouse cytomegalovirus M45) may have evolved to subvert CD8 + T cell cross-priming. In turn, scaffold proteins such as RIPK1, which are an assemblage of multiple domains (RHIM domain, death domain, and kinase domain), may have evolved to coordinate cell death and innate signaling modules (39), together orchestrating adaptive immunity. Thus, investigation and targeting of scaffold proteins at the intersection of cell death pathways and hostdefense pathways may provide new therapeutic opportunities in the field of immunotherapy. using Nanostring tools (grants INCa-DGOS-4654, SIRIC11-002, ANR-10-IDEX-0001-02 PSL, and ANR-11-LBX-0044). (Fig. 1A and   fig. S3A ). Autoimmune disease was apparent by 6 to 8 months of age, accompanied by the infiltration of immune cells into nonlymphoid tissues (Fig. 1B) , the production of autoantibodies (Fig. 1C) , and glomerular nephritis ( fig. S3B ). Rag2
-/-mice reconstituted with bone marrow (BM) from Helios -/-donors also developed autoimmunity ( fig. S4 ), indicating a lymphocyte-intrinsic effect.
Although Helios -/-mice did not develop overt signs of autoimmunity until 5 to 6 months of age, upon challenge with viral infection by LCMVArmstrong (LCMV, lymphocytic choriomeningitis virus), both young (2 months) and older (6 months) Helios -/-mice but not Helios +/+ mice developed inflammatory and autoimmune changes characterized by increased levels of T FH and GC B cells (Fig. 1D ) and immunoglobulin G (IgG) deposition in the kidney (Fig. 1E) (Fig. 2, A and B) , autoantibody production (Fig. 2C) , and immune cell infiltration ( fig. S11) 
